Efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of platinum resistant recurrent ovarian cancer: a retrospective observational study.

ABSTRACT:

Objective

To report on the efficacy of pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide used in combination for patients with platinum resistant recurrent ovarian cancer in community practice.

Methods

This retrospective observational study was conducted at a single gynecologic oncology practice in Albany, NY. Patients that had a diagnosis of platinum-resistant ovarian cancer (PROC) received intravenous pembrolizumab (200 mg) and bevacizumab (15 mg/kg) every 3 weeks, with oral cyclophosphamide (50 mg) once daily during the treatment cycle until disease progression, toxicity, or withdrawal of consent. Treatment response was determined using imaging and CA-125 levels.

Results

Nineteen patients with PROC were included. There were 17 high grade serous and 2

SUBMITTER: Steck AR 

PROVIDER: S-EPMC12271593 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature